Abstract / Summary
Abstract Background This study explores fatigue in adolescents and young adults (AYAs) diagnosed with myeloproliferative neoplasms (MPNs), a population facing unique developmental and psychosocial challenges. The objectives were to examine age-related differences in fatigue among patients with MPNs (QUAN), explore its manifestations, impact on daily life, and management among AYAs (QUAL), and integrate these findings to provide a comprehensive understanding of fatigue in this population (QUAN+QUAL). Methods A convergent mixed methods design was employed, integrating quantitative data from medical records, including fatigue scores from the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score, with qualitative data gathered through semi-structured interviews with AYA patients. Results Quantitative analysis revealed that AYAs reported significantly higher fatigue levels than older adults (57% vs. 43%; p = 0,027). Moreover, fatigue was significantly associated with early satiety ( p = 0.0036), inactivity ( p = 0.034), and pruritus ( p = 0.014), suggesting that targeted management of these symptoms may help alleviate fatigue in this population. In contrast, fatigue in older adults correlated broadly with all subitems, indicating its association with overall symptom burden rather than specific symptom clusters. Qualitative findings underscored fatigue as a multidimensional and pervasive symptom, frequently impairing AYAs' ability to work and engage in daily activities. Pharmacologic treatments, including those targeting MPN biomarkers, were commonly viewed as ineffective for managing fatigue. In contrast, regular physical activity emerged as the most beneficial strategy, often enhanced by structured sleep routines, healthy eating habits, and restorative napping. Conclusion These findings highlight the need for age-specific, non-pharmacological approaches to fatigue management in AYA patients with MPNs. Tailored interventions, particularly those promoting physical activity, may improve symptom control and overall quality of life in this understudied and vulnerable patient population.